595nm Pulsed Dye Laser: An Alternative to Treat Basal Cell Carcinomas
INTRODUCTION: Basal cell carcinoma (BCC) is the most common cutaneous malignancy. Proffered treatment for these lesions is surgery. Based on patient’s age, drug allergies, and place of lesions, surgery may not be the best option, and alternative treatments should be considered. Pulsed dye laser (PDL) may be a good alternative therapy. The aim of the present study was to determine the effectiveness and safety of this laser in the treatment of BCCs in Iranian patients.
METHODS: Patients with definite diagnosis of BCC enrolled in the study. For each patient, one lesion proved to be superficial, or nodular BCC via histopathology was treated with PDL for four sessions and after the last session, re-biopsy was done to determine any remnant of tumor. All patients were followed for 6 to 13 months to capture any recurrence of as soon as possible.
RESULTS: A total of 12 patients including eight male and four female were selected. All patients completed the study in accordance to the treatment protocol. All patients cleared clinically resulting flat hypo pigmented scar, but in pathology, two patients showed remnants of tumor and were referred for surgery. No side effects, but mild erythema and irritation were noted in all patients. No recurrences were found during the follow up period.
CONCLUSION: It seems that PDL may be an effective alternative therapy for some subtypes of BCCs with acceptable safety profile. Further studies with larger sample sizes are required to support this opinion.
Chinem VP, Miot HA. Epidemiology of basal cell carcinoma. An Bras Dermatol 2011;86(2):292-305.
Nseir A, Esteve E. [Basal cell carcinoma]. Presse Med 2008;37(10):1466-1473.
Tilli CM, van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005;152(6): 1108-1124.
Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients.J Invest Dermatol 2005;124(3):505-513.
Sharpe G. Skin cancer: prevalence, prevention and treatment. Clin Med 2006;6(4):333-4.
Buljan M, Bulat V, Situm M, Mihic LL, Stanic-Duktaj S. Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat 2008. 2008;47(1):25-30.
Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebocontrolled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010;20(4):482-8.
Van Hezewijk, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, Willemze R, Marijnen CA, Efficacy of a hypofractionated Schedule in electron beam radiotherapy far epithelial skin cancer: Analysis of 434 cases. Radiother Oncol 2010;95(2):245-9.
Zeichner JA, Patel RV, Birge MB. Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. J Clin Aesthet Dermatol 2011;4(5):39-43.
Sanmartin V, Aguayo R, Baradad M, Casanova JM. Oral Acitretin and Topical Imiquimod as Neoadjuvant Treatment for Giant Basal Cell Carcinoma. Actas Dermosifiliogr 2011. may 13 [Epub ahead of print].
Stebbins WG, Hanke CW. MAL-PDT for difficult to treat nonmelanoma skin cancer. Dermatol Ther 2011;24(1):82-93.
Lien MH, Sondak VK. Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer 2011;2011:571734. Epub 2011 Jan 9.
Murchison AP, Walrath JD, Washington CV. Nonsurgical treatments of primary, non-melanoma eyelid malignancies: a review. Clin Experiment Ophthalmol 2011;39(1):65-83.
Prokosch V, Thanos S, Spaniol K, Stupp T. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Ophthalmol 2011;249(1):121-125.
Sebaratnam DF, Venugopal SS, Murrell DF. A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes. J Eur Acad Dermatol Venereol 2011;25(1): 117-118.
Allison KP, Kiernan MN, Waters RA, Clement RM. Pulsed dye laser treatment of superficial basal cell carcinoma: realistic or not? Lasers Med Sci 2003;18(2):125-126.
Campolmi P, Mavilia L, Bonan P, Cannarozzo G, Lotti TM. 595 nm pulsed dye laser for the treatment of superficial basal cell carcinoma. Lasers Med Sci 2005;20(3-4):147-148.
Shah SM, Konnikov N, Duncan LM, Tannous ZS. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med 2009;41(6):417-422.
Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med 2011;43(2):72-78.
Authors who publish with this journal agree to the following terms:
Upon publication, each author agrees that the “Laser application in Medical Sciences Research Center” is the copyright owner of the material published in “Journal of Lasers in Medical Sciences”. The users are free to copy, distribute, and display the work; to make any reasonable noncommercial use of the work, subject to proper attribution of authorship and ownership of the rights. Authors may use their material in presentations and subsequent publications they write or edit themselves, provided that “Journal of Lasers in Medical Sciences” is notified in writing and is acknowledged as the original publication.
b. Statement of Authorship
This statement acknowledges that each undersigned author has made a substantial contribution to the manuscript and is willing to take public responsibility for its contents. Author(s) attest that all persons designated as authors qualify for authorship and all those who qualify are listed. The corresponding author takes responsibility for the integrity of the work as a whole